Opdivo vs Jakafi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Jakafi costs 28% less per claim than Opdivo ($11432.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Jakafi at $2.7B.
| Metric | Opdivo | Jakafi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $15,821 | $11,432* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.1B | $2.7B |
| Total Claims | 324,000 | 236,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 15.8% | 11.2%* |
| Generic Available | Yes | No |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 66,000 | 22,000 |
Jakafi costs 28% less per claim than Opdivo ($11432.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Jakafi at $2.7B.
Explore More
Comparing Opdivo and Jakafi on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.